Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from NVAX

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine.

Benzinga

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.

Benzinga

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots

Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, just days before it reconvenes to vote on COVID-19 shots and other routine pediatric vaccine recommendations.

Benzinga

Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'

The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market "within months," according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr.

Benzinga

Novavax Shares Are Trading Higher Thursday: What's Going On?

Novavax, Inc. (NASDAQ:NVAX) shares are trading lower Thursday after the company announced it has extended its $225 million convertible notes deal. Additionally, B of A securities downgraded the stock yesterday from a Neutral rating to a Underperform rating and cut its price target from $9 to $7.

Benzinga

Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a year ago, beating the consensus of $156.29 million.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector

Shares of Novavax Inc (NASDAQ:NVAX) are trading lower Friday morning, appearing to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna Inc (NASDAQ:MRNA) reported disappointing second-quarter financial results and cut its full-year forecast.

Benzinga

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate.

Benzinga

Analysts Think These Stocks Could More Than Double in Value

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

MarketBeat

Options Alert: Why Novavax (NVAX) Could Be the Biotech Hero of Trump 2.0

While vaccine-related investments have broadly suffered following Trump’s electoral victory, NVAX stock may represent a compelling compromise.

Barchart

3 Under-the-Radar Stocks That Could Be Tomorrow's Blue Chips

Investors will increasingly focus on upcoming economic data to gauge soft landing odds that have helped drive stock performance in 2024. Given an evolving macroeconomic landscape, it could be wise to invest in under-the-radar socks Workday (WDAY), CrowdStrike (CRWD), and Novavax (NVAX), which could be tomorrow’s blue chips. Read more.

StockNews.com

2 Biotech Stocks That Are Screaming “SELL ME!”

The biotech sector is witnessing the headwinds from the banking crisis, layoffs, and the Inflation Reduction Act. So, fundamentally weak biotech stocks Ginkgo Bioworks Holdings (DNA) and Novavax (NVAX) might be best avoided. Read on.

StockNews.com

Is Novavax a Buy, Sell, or Hold Following FDA Decision?

Despite the FDA authorization of Novavax’s (NVAX) two-dose vaccine, the possible side effects and slow vaccine uptake keep the stock under pressure. So, let’s evaluate if it is worth adding the stock to one’s portfolio now. Read on….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Novavax (NVAX) Down As EU Adds Side Effects To COVID Jab Label

Shares of Novavax (NASDAQ: NVAX) fell 26.2% on Jul 14, after the European Medicines Agency's (TSE: EMA) Pharmacovigilance Risk Assessment Committee ("PRAC") updated the product label of Nuvaxovid, the company's COVID-19 vaccine, to include some potential side effects like severe aller

Benzinga

Novavax' Sees Conditional Approval Of COVID-19 Vaccine Booster In Australia As US FDA Delays Its Decision

The Australian regulatory authority has conditionally approved Novavax Inc's (NASDAQ:NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over. The provisional registration was based on data from Novavax's Phase 2 trial conducted in Australia, wherein a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six months after…

Benzinga

Why Novavax Stock Is Falling Today

Novavax Inc (NASDAQ: NVAX) shares are trading lower Thursday following reports that the U.S. Food and Drug Administration's decision on the company's COVID-19 vaccine could be delayed to review manufacturing changes.

Benzinga

HC Wainwright Says Non-mRNA COVID-19 Option Underappreciated

HC Wainwright says safety concerns were noted for Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, but the strength of data showed that benefit outweighs risks.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Novavax Stock Is Trading Higher Today

Novavax Inc (NASDAQ: NVAX) shares are trading higher Wednesday after a committee of independent U.S. Food and Drug Administration (FDA) vaccine advisors voted to recommend Novavax's COVID-19 vaccine for Emergency Use Authorization (EUA).

Benzinga

Novavax's COVID-19 Vaccine For Adults Over 18 Backed By FDA Advisors: What's Next?

Novavax, Inc. (NASDAQ: NVAX) announced the U.S.

Benzinga

What's Going On With Novavax Stock Today?

Novavax Inc (NASDAQ: NVAX) shares have been halted since the pre-market session as the U.S. Food and Drug Administration holds a meeting to determine the fate of the company's COVID-19 vaccine.

Benzinga

$100 Invested In Novavax 5 Years Ago Would Be Worth This Much

Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 9.78% on an annualized basis producing an average annual return of 19.75%. Currently, Novavax has a market capitalization of $3.69 billion.

Benzinga

What Are Whales Doing With Novavax

Someone with a lot of money to spend has taken a bullish stance on Novavax (NASDAQ:NVAX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Novavax Has Limited Pipeline Upside, Says BofA Analyst: What's Next?

Although Novavax, Inc’s (NASDAQ: NVAX) shares have tanked 59% year to date, there is still room for a further decline, according to BofA Securities. The Novavax Analyst: Alec Stranahan initiated coverage of Novavax with an Underperform rating and a price target of $35.

Benzinga

Check Out What Whales Are Doing With NVAX

1 2 3

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

304 stories

Merck

284 stories

Health and Human Services

249 stories

CRWD

246 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.